CLINICAL TRIALS PROFILE FOR MODAFINIL
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Modafinil
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT03182413 ↗ | Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation | Completed | Institut de recherche biomédicale des armées (IRBA), Bretigny sur Orge, France | Phase 1 | 2015-09-01 | Study Objectives: THN102 is a new combination between modafinil and flecainide low-dose, a documented glial connexin inhibitor. Efficacy of THN102 was compared to modafinil and to placebo on parameters impaired by total sleep deprivation (SD, lasting 40h). Methods: 20 healthy male subjects participated in a double-blind, randomised, incomplete-block 3-period cross-over trial involving 5 treatments (n=12 per group): placebo (PBO), modafinil 100 mg (MOD), and combinations THN102 (modafinil 100 mg and 1, 3 or 9 mg flecainide as THN1, THN3 and THN9), as 3 oral doses over 18h. |
| New Combination | NCT03182413 ↗ | Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation | Completed | Theranexus | Phase 1 | 2015-09-01 | Study Objectives: THN102 is a new combination between modafinil and flecainide low-dose, a documented glial connexin inhibitor. Efficacy of THN102 was compared to modafinil and to placebo on parameters impaired by total sleep deprivation (SD, lasting 40h). Methods: 20 healthy male subjects participated in a double-blind, randomised, incomplete-block 3-period cross-over trial involving 5 treatments (n=12 per group): placebo (PBO), modafinil 100 mg (MOD), and combinations THN102 (modafinil 100 mg and 1, 3 or 9 mg flecainide as THN1, THN3 and THN9), as 3 oral doses over 18h. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Modafinil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00033046 ↗ | Evaluation of Modafinil as a Cocaine Treatment Medication and Interactions With Cocaine - 1 | Unknown status | National Institute on Drug Abuse (NIDA) | Phase 1 | 2001-06-01 | The purpose of this study is to evaluate modafinil, a cocaine treatment medication, and its interactions with intravenous (IV) cocaine. |
| NCT00042848 ↗ | Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 2002-08-01 | RATIONALE: Modafinil may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy. The effectiveness of modafinil in relieving chemotherapy-related fatigue is not yet known. PURPOSE: This randomized phase III trial is studying the effectiveness of modafinil in treating fatigue in patients who are receiving chemotherapy for cancer. |
| NCT00042848 ↗ | Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer | Completed | Gary Morrow | Phase 3 | 2002-08-01 | RATIONALE: Modafinil may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy. The effectiveness of modafinil in relieving chemotherapy-related fatigue is not yet known. PURPOSE: This randomized phase III trial is studying the effectiveness of modafinil in treating fatigue in patients who are receiving chemotherapy for cancer. |
| NCT00052286 ↗ | Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer | Completed | Cephalon | N/A | 2002-09-01 | RATIONALE: Modafinil may be effective in relieving fatigue and improving behavioral changes such as memory loss in patients who have undergone treatment for primary brain cancer. The effectiveness of modafinil in relieving fatigue and improving behavioral change is not yet known. PURPOSE: This randomized clinical trial is comparing how well two different doses of modafinil work in treating fatigue and behavioral changes in patients who have undergone treatment for primary brain cancer. |
| NCT00052286 ↗ | Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer | Completed | National Cancer Institute (NCI) | N/A | 2002-09-01 | RATIONALE: Modafinil may be effective in relieving fatigue and improving behavioral changes such as memory loss in patients who have undergone treatment for primary brain cancer. The effectiveness of modafinil in relieving fatigue and improving behavioral change is not yet known. PURPOSE: This randomized clinical trial is comparing how well two different doses of modafinil work in treating fatigue and behavioral changes in patients who have undergone treatment for primary brain cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Modafinil
Condition Name
Clinical Trial Locations for Modafinil
Trials by Country
Clinical Trial Progress for Modafinil
Clinical Trial Phase
Clinical Trial Sponsors for Modafinil
Sponsor Name
